Identifies, develops, and distributes reagents and tools for scientific research. Provides primary and secondary antibodies, essential for various biological assays. Now — the numbers.
The company is still in the product-building phase: its spending runs above its sales. That only changes once the product starts selling at scale.
Average growth of 12% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 11.3× for every dollar of annual revenue.
No analyst target is on record for this company.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 12% a year on average.
Sales run at $489.0M a year. A small number, but proof the product has real buyers.
A loss of $11.5M against $489.0M in annual sales. And on top of that, sales fell from the year before.
The price action doesn’t yet back an upward turn. Council score: 0/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.